APA (7th ed.) Citation

M, D., S, S., F, P., F, V., V, R., A, P., . . . S, T. (2026). The protease inhibitor gabexate mesylate targets Raf kinase inhibitor protein and reverses epithelial-mesenchymal transition in triple-negative breast cancer cells. Frontiers in oncology, 16, 1713273. https://doi.org/10.3389/fonc.2026.1713273

Chicago Style (17th ed.) Citation

M, Deserti, Sabbioni S, Poli F, Vasuri F, Relli V, Palloni A, Deiana C, Brandi G, and Tavolari S. "The Protease Inhibitor Gabexate Mesylate Targets Raf Kinase Inhibitor Protein and Reverses Epithelial-mesenchymal Transition in Triple-negative Breast Cancer Cells." Frontiers in Oncology 16 (2026): 1713273. https://doi.org/10.3389/fonc.2026.1713273.

MLA (9th ed.) Citation

M, Deserti, et al. "The Protease Inhibitor Gabexate Mesylate Targets Raf Kinase Inhibitor Protein and Reverses Epithelial-mesenchymal Transition in Triple-negative Breast Cancer Cells." Frontiers in Oncology, vol. 16, 2026, p. 1713273, https://doi.org/10.3389/fonc.2026.1713273.